Authors
Latest:
PARP-1 Inhibitors and Their Emerging Role in the Treatment of Lung CancerLung cancer is one of the leading causes of death worldwide. The standard of care for advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) includes platinumbased chemotherapy.
Latest:
Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient CancersNilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />
Latest:
Efficacy Seen When Daratumumab is Added to Treatment in Multiple MyelomaIn an interview with Targeted OncologyTM Nina Shah, MD, discusses the findings from several trials that show the efficacy of daratumumab for patients with multiple myeloma.
Latest:
The Future of CAR T-Cell Therapy for Acute Lymphoblastic LeukemiaNitin Jain, MD, discusses future improvements he anticipates for autologous and allogeneic chimeric antigen receptor T-cell therapies for B-cell acute lymphoblastic leukemia and other hematologic malignancies.
Latest:
DFS vs OS Primary Endpoints in KEYNOTE 564Scott Tykodi, MD, PhD, discusses using DFS as a primary end point in trials, as well as the usage of biomarkers.
Latest:
First-Line ICI-Based Combinations for mRCC With Sarcomatoid FeaturesRenal cancer experts conclude their discussion by examining first-line immune checkpoint inhibitor-based combination therapies for metastatic renal cell carcinoma with sarcomatoid features, and offer their final insights on the current state and future directions of RCC treatment.
Latest:
Novel Targets in Relapsed and Relapsed/Refractory Multiple MyelomaCurrent approaches to the management of multiple myeloma (MM), in particular the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), have improved the survival of patients.
Latest:
Benefits to Stem Cell Transplant for Patients With Multiple MyelomaNoa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses the rationale for selecting stem cell transplant as treatment over a chemotherapy regimen for patients with multiple myeloma.
Latest:
Dr. Kauff Discusses Remaining Questions in the Treatment of Patients With Uterine CancerNoah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses unanswered questions regarding the treatment of patients with uterine cancer.
Latest:
Highlighting the Current Treatment Strategies for Patients With Multiple MyelomaNoopur Raje, MD, discusses the current treatment options for patients diagnosed with multiple myeloma. At this time, a number of FDA-approved drugs and different combinations are available.
Latest:
Expert Discusses the BOSTON Trial of Selinexor in Multiple MyelomaNoopur S. Raje, MD, discusses the results of the BOSTON trial of selinexor, bortezomib, and dexamethasone in patients with multiple myeloma.
Latest:
Dr. Hashemi Sadraei Discusses the Challenges of Treating HPV-Induced TumorsNooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses the challenges of treating HPV-induced tumors.
Latest:
The Significance of the Ipilimumab/Nivolumab Findings in MelanomaNorman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.
Latest:
BGB324 With Pembrolizumab or Dabrafenib/Trametinib in MelanomaOddbjørn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma.
Latest:
Role of Novel Subcutaneous Daratumumab in Multiple MyelomaHow the recent FDA approval of the subcutaneous formulation of daratumumab in multiple myeloma will affect patients and oncologists from practical and clinical standpoints.
Latest:
The Treatment of High-Risk Smoldering MyelomaOla Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
Latest:
Challenges With CAR T-Cell TherapyDuring the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.
Latest:
Future Directions of BiTE and CAR T for mCRPCA look toward the future development of bispecific T-cell engages (BiTEs) and CAR T-cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Novel Therapies for <em>T315I</em>-Mutant CMLThe use of tyrosine kinase inhibitors (TKIs) to inhibit BCR-ABL protein in chronic myeloid leukemia (CML) is one of the major milestones in modern oncology.
Latest:
Options for Patients With Melanoma Who Have Exhausted Standard TherapiesOmid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses options for patients with melanoma who have exhausted standard therapies.
Latest:
Advancing Melanoma Treatment: Hamid on Lifileucel's RoleIn this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.
Latest:
CAR T-Cells in the Treatment Landscape of Mantle Cell LymphomaOwen O’Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL). This can be tricky for a number of reasons, but O’Connor is hopeful that there are treatment regimens for this patient population that can work.
Latest:
Dr. Padmanee Sharma on the Evolving Landscape of Immune Response and PD-L1 as an Ineffective BiomarkerPadmanee Sharma discusses the constantly shifting landscape of immune response and how it differs from patient to patient. Sharma says in order to best treat a patient with bladder cancer, oncologists have to consider that immune response in patients will never be the same day to day.
Latest:
DLBCL in Older Adults: Applying the Goldilocks PrincipleExploration of aging biomarkers such as senescence-associated secretory phenotype and epigenetic clocks can inform appropriate patient and treatment selection in the future.
Latest:
The Impact of CAR-T Cell Therapy in Relapsed/Refractory Multiple MyelomaThe paradigm for management of relapsed myeloma is evolving rapidly with a plethora of treatment options based on results of clinical trials. One explosive area of scientific and clinical research is the investigation of chimeric antigen receptor T-cell therapy.
Latest:
Dr. Pamela Kunz on the Effectiveness of Immunotherapies and Their Promising FuturePamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.
Latest:
Key Takeaways from 2024 ASCO GI Cancers SymposiumFollowing their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.
Latest:
Evaluating Therapy With Encorafenib, Binimetinib, and Ribociclib in MelanomaPaola A. Ascierto, MD, medical oncologist, director of Melanoma Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori “Fondazione G. Pascal,” discusses results of a phase Ib/II dose-escalation study evaluating triple combination therapy with encorafenib, binimetiinib, and ribociclib (Kisquali) in patients with <em>BRAF V600</em> solid tumors and melanoma.
Latest:
Combination Encorafenib Plus Binimetinib in Patients With MelanomaPaolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.
Latest:
Ghia Highlights 5-Year Follow-Up Data From CAPTIVATE in CLL/SLLPaolo Ghia, MD, PhD, discusses the key takeaways from 5-year data follow-up data from the phase 2 CAPTIVATE trial of ibrutinib plus venetoclax for the treatment of patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma.
